MOTS-c – Comprehensive Research Overview (2026)
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid mitochondria-derived peptide (MDP) encoded within mitochondrial DNA. It acts as a systemic hormone-like signal, translocating to the nucleus under metabolic stress to regulate gene expression. MOTS-c is primarily researched for insulin resistance, obesity, metabolic syndrome, and aging, functioning as a potent exercise-mimetic. Early Phase 1 safety trials have confirmed tolerability in humans.
→ View MOTS-c (for laboratory research use only)
Chemical Structure and Properties
- Sequence: MRWQEMGYIFYPRKLR
- Molecular Weight: ≈2,174 Da
- Form: Lyophilized powder for subcutaneous injection
- Key Feature: Encoded in mitochondrial DNA; acts as a mitochondria-to-nucleus retrograde signal
Mechanism of Action
- Inhibits the folate cycle and de novo purine synthesis, activating AMPK.
- Translocates to the nucleus under stress, regulating gene expression via ATF1 and NRF2 pathways.
- Promotes GLUT4 translocation and glucose uptake in skeletal muscle.
- Enhances mitochondrial biogenesis and fatty acid oxidation.
- Coordinates mitochondrial–nuclear communication to improve metabolic flexibility.
Clinical Evidence and Research Findings
Extensive preclinical data demonstrate MOTS-c’s ability to reverse diet-induced insulin resistance, reduce obesity, and improve exercise capacity in rodent models. Circulating MOTS-c levels decline with age and are elevated by exercise in humans. Phase 1 safety trials have confirmed tolerability. It is one of the few mitochondria-derived peptides with confirmed human safety data.
→ Interested in researching MOTS-c? View Product Options
Benefits (Research & Clinical Observations)
- Improved insulin sensitivity and glucose metabolism
- Enhanced exercise capacity and endurance
- Reduced adiposity and improved body composition
- Anti-aging effects via mitochondrial signaling
- Potential for sarcopenia and metabolic syndrome research
Typical Dosing Protocols (Off-Label / Research)
- Preclinical: 0.5–5 mg/kg subcutaneous or intraperitoneal
- Off-label human protocols: 5–10 mg subcutaneous daily or every other day
- Cycles: 4–12 weeks
Safety Profile
Phase 1 trials confirmed tolerability. Preclinical safety profile is favorable. No significant organ toxicity at effective doses. Long-term human data are limited.
MOTS-c vs BAM15 vs SS-31 – Quick Comparison
| Aspect | MOTS-c | BAM15 | SS-31 |
|---|---|---|---|
| Origin | Mitochondrial DNA peptide | Synthetic small molecule | Synthetic tetrapeptide |
| Primary Target | AMPK / nuclear gene expression | Mitochondrial uncoupling | Cardiolipin / inner membrane |
| Best For | Insulin resistance, aging, exercise | Fat loss, metabolic syndrome | Heart failure, renal protection |
| Human Data | Phase 1 safety confirmed | None | Phase 2/3 (Breakthrough Therapy) |
Summary
MOTS-c is a mitochondria-derived peptide with a unique mechanism of action, acting as a retrograde signal to coordinate metabolic adaptation. Its exercise-mimetic properties, confirmed human safety, and anti-aging potential make it one of the most exciting compounds in mitochondrial and metabolic research. As with all compounds in this library, MOTS-c is not an approved drug and should only be considered under qualified medical supervision.
For Laboratory Research Use View MOTS-c →
Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.